Dutch life sciences venture capital firm Forbion has raised over €2 billion across two new funds: Forbion Growth Opportunities III and Forbion Ventures VII, bringing the firm’s total assets under management to €5 billion. Both funds exceeded their initial targets, securing €1.2 billion and €890 million, respectively.
Forbion Growth Opportunities Fund III will focus on investing in later-stage biopharma companies in Europe and North America, particularly those developing novel therapies in areas of high medical need. Meanwhile, their Venture Fund VII will build a portfolio of innovative biotech companies, including both existing firms and new ventures founded around assets from pharmaceutical or academic institutions.
Advertisement
Driving Future Medical Innovation
With the newly raised capital, the VC aims to invest in approximately 15 companies per fund, backing management teams developing transformative medical therapies. The firm’s portfolio already includes groundbreaking work in gene therapy, immunotherapies, and disease-modifying drug development.
Forbion’s co-founder and Managing Partner Sander Slootweg emphasized the importance of supporting high-potential biotech firms to drive impactful returns and advance the future of medicine.
Backing in Volatile Markets
Despite challenging market conditions, the funds have attracted strong demand from new and existing investors. Robbert van de Griendt, General Partner, credited Forbion’s success to its consistent historical returns and impressive track record of exits, highlighting the investors’ confidence in the firm’s specialized investment strategy.
The dutch VC continues to lead the charge in life sciences venture capital, managing investments across the entire biopharmaceutical development spectrum while contributing to advancements in sustainability through its BioEconomy fund strategy, targeting food, agriculture, and environmental technologies.
